



Sections 297(2) and 298(2), Financial Markets Conduct Act 2013

Fisher & Paykel Healthcare Corporation Limited
13 September 2023
10 February 2023

Paul Nigel Shearer
Fisher & Paykel Healthcare Corporation Limited
Vice President - Sales & Marketing

(a) Options to acquire Ordinary Shares	
(b) Performance Share Rights	
	Beneficial
(a) 201,698 Options	
(b) 73,136 Performance Share Rights	
(a) 260,522 Options	
(b) 98,734 Performance Share Rights	
	Paul Nigel Shearer
	Paul Nigel Shearer

Two

	(a) 12 September 2023
	(b) 12 September 2023
	(a) Issue of Options
	(b) Issue of Performance Share Rights
	(a) \$nil
	(b) \$nil

	(a) 58,824 Options (b) 25,598 Performance Share Rights
Number of financial products to which the transaction related: <i>If the issuer has a financial products trading policy that prohibits directors or senior managers from trading during any period without written clearance (a closed period) include the following details—</i>	
Whether relevant interests were aquired or disposed of during a closed period:	
Whether prior written clearance was provided to allow the aquisition or disposal to proceed during the closed period:	
Date of the prior written clearance (if any):	
Summary of other relevant interests after acquisition or disposal:	
Class of quoted financial products:	Ordinary Shares
Nature of relevant interest:	Beneficial
<i>For that relevant interest,-</i>	
Number held in class:	384,968
Current registered holder(s):	Paul Nigel Shearer, Shearer Family Trust
<i>For a derivative relevant interest,-</i>	
Type of derivative:	
Details of derivative,-	
The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):	
A statement as to whether the derivative is cash settled or physically settled:	
Maturity date of the derivative (if any):	
Expiry date of the derivative (if any):	
The price's specified terms (if any):	
Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:	
<i>For that derivative relevant interest,-</i>	
Parties to the derivative:	
If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:	
Cerification	
I certify that, to the best of my knowledge and belief, the information contained in this disclosure is correct and that I am duly authorised to make this disclosure by all persons for whom it is made.	
Signature of director or officer:	
Date of signature:	
or	
Signature of person authorised to sign on behalf of director or officer:	Raelene Leonard
Date of signature:	13 September 2023
Name and title of authorised person:	Raelene Leonard, Company Secretary